Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERCURY trial of neoadjuvant retifanlimab plus platinum-etoposide before surgery in resectable Merkel cell carcinoma
2024-516316-13-00Phase 2Authorised
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Jan 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retifanlimab, etoposide, carboplatin and cisplatin in Merkel cell carcinoma (MCC), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Pathological complete response rate. Planned start Jan 2025; status: authorised.
02
Drugs
retifanlimabetoposidecarboplatincisplatin
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on 2024-516316-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516316-13-00.